Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 3/20 | 0.56 |
| ▸ | WEE1 | P30291 | 9/20 | 0.55 |
| ▸ | TNK2 | Q07912 | 3/20 | 0.52 |
| ▸ | SRC | P12931 | 2/20 | 0.52 |
| ▸ | LCK | P06239 | 1/20 | 0.52 |
| ▸ | KDR | P35968 | 1/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | EGFR | P00533 | 4/20 | 0.51 |
| ▸ | BRD4 | O60885 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2480201 | 0.97 | KCNH2 (0.58) | KCNH2WEE1TNK2SRCLCK | |
| SCHEMBL2501396 | 0.93 | WEE1 (0.55) | KCNH2WEE1TNK2CYP3A4EGFR | |
| SCHEMBL2502965 | 0.91 | WEE1 (0.53) | KCNH2WEE1TNK2CYP3A4EGFR | |
| SCHEMBL18117561 | 0.91 | KCNH2 (0.52) | KCNH2WEE1TNK2SRCLCK | |
| SCHEMBL2501179 | 0.90 | TNK2 (0.54) | KCNH2WEE1TNK2EGFR | |
| SCHEMBL2507027 | 0.90 | KCNH2 (0.50) | KCNH2WEE1TNK2SRCLCK | |
| SCHEMBL2479657 | 0.90 | KCNH2 (0.50) | KCNH2WEE1TNK2SRCLCK | |
| SCHEMBL2502950 | 0.89 | LCK (0.59) | KCNH2WEE1TNK2SRCLCK | |
| SCHEMBL2500634 | 0.89 | KCNH2 (0.54) | KCNH2WEE1TNK2CYP3A4EGFR | |
| SCHEMBL2507539 | 0.89 | EGFR (0.51) | KCNH2WEE1TNK2SRCLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575179-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2013-11-05 | — | — | US | claimed |
| EP-2376494-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVES | MSD K.K. (JP) | 2011-10-19 | — | — | EP | claimed |
| US-20110245229-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | MSD K.K. (JP) | 2011-10-06 | — | — | US | claimed |
| WO-2010067888-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-06-17 | — | — | WO | claimed |
| US-8575179-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2013-11-05 | — | — | US | disclosed |
| US-8575179-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2013-11-05 | — | — | US | disclosed |
| US-8575179-B2 | Dihydropyrazolopyrimidinone derivatives | MSD K.K. (JP) | 2013-11-05 | — | — | US | disclosed |
| EP-2376494-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVES | MSD K.K. (JP) | 2011-10-19 | — | — | EP | disclosed |
| US-20110245229-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | MSD K.K. (JP) | 2011-10-06 | — | — | US | disclosed |
| US-20110245229-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | MSD K.K. (JP) | 2011-10-06 | — | — | US | disclosed |
| US-20110245229-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | MSD K.K. (JP) | 2011-10-06 | — | — | US | disclosed |
| WO-2010067888-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010067888-A1 | DIHYDROPYRIMIDOPYRIMIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245229-A1 | DIHYDROPYRAZOLOPYRIMIDINONE DERIVATIVES | WEE2, WEE1, CDKL1 | KCNH2 2114/4885WEE1 2/4885TNK2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.